Vyndamax® (tafamidis)
for Transthyretin Amyloid Cardiomyopathy

Vyndamax (tafamidis) is an oral prescription medicine used to reduce death or hospitalization related to heart problems in adults with cardiomyopathy from wild-type or hereditary transthyretin-mediated amyloidosis (ATTR-CM). Vyndamax stabilizes abnormal transthyretin, a protein linked to ATTR-CM, preventing harmful amyloid protein deposits in the heart and slowing disease progression.

Heart
Medication Guide Icon Medication Guide
TV Commercial Icon TV Commercial
Patient Website Icon Patient Website
Efficacy Data Icon Efficacy Data
New Articles Icon New Articles
Savings and Support Icon Savings and Support
Company MD Payments Icon Company MD Payments
Clinical Trials Icon Clinical Trials
Adverse Event Report Icon Adverse Event Report
Other top medicines used to treat Transthyretin Amyloid Cardiomyopathy - ATTR CM